Table 3.
List of metabolomics datasets.
| Published year | Coverage | Research objective | Grouping design | Sample source | Sample type | Analytic method | Reference |
|---|---|---|---|---|---|---|---|
| 2016 | Targeted | Diagnosis | ICP vs GDM vs Control | Human body | Serum | LC-MS/MS | (38) |
| 2017 | Untargeted | Diagnosis | ICP vs Control | Human body | Urine | LC-MS | (39) |
| 2018 | Untargeted | Diagnosis | ICP vs Control | Human body | Hair | GC-MS | (40) |
| 2018 | Targeted | Diagnosis | mild ICP vs severe ICP vs Control | Human body | Urine | LC-MS/MS | (41) |
| 2018 | Targeted | Diagnosis | ICP vs Control | Human body | Serum | LC-MS/MS | (42) |
| 2019 | Targeted | Diagnosis | AHP vs ICP vs Control | Human body | Urine | LC-MS/MS | (43) |
| 2019 | Targeted | Pathogenesis | G60, G90, and L0 | Pig | Serum | LC-MS/MS | (44) |
| 2021 | Untargeted | Diagnosis | ICP vs Control | Human body | Placenta | LC-MS | (45) |
| 2021 | Targeted | Diagnosis | mild ICP vs severe ICP vs Control | Human body | Plasma | LC-MS/MS | (46) |
| 2021 | Targeted | Diagnosis | ICP1 vs ICP2 vs ICP3 vs ICP4 vs Control | Human body | Serum | LC-MS/MS | (47) |
| 2022 | Untargeted | Pathogenesis | 17α-Ethinyl estradiol, Paeoniflorin and Control | Rat | Serum; Faeces | LC-MS | (48) |
| 2022 | Untargeted | Pathogenesis | ICP vs Control | Human body | Plasma | LC-MS/MS | (49) |
| 2022 | Untargeted | Pathogenesis | mild ICP vs severe ICP vs Control | Human body | Plasma | LC-MS/MS | (50) |
| 2022 | Targeted | Diagnosis | AHP vs ICP vs Control | Human body | Serum | LC-MS/MS | (51) |
| 2022 | Targeted | Pathogenesis | Wt-Ve,WT-EE,TR-Ve,TR-EE ethinylestradiol (EE) administration to Mrp2-deficient (TR) rats and their wild-type (WT) controls | Rat | Plasma | LC-MS | (52) |
| 2023 | Untargeted | Pathogenesis | ICP vs Control | Human body | Placenta; Serum; Urine | LC–MS/MS | (53) |